Black Friday saleUp to 70% OFF
BIONTECH SE SPON ADS EACH REP 1 ORD SHSBIONTECH SE SPON ADS EACH REP 1 ORD SHSBIONTECH SE SPON ADS EACH REP 1 ORD SHS

BIONTECH SE SPON ADS EACH REP 1 ORD SHS

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

0A3M fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0A3M does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company